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Clinical features and outcomes of 134 Brazilians
with acute promyelocytic leukemia who received
ATRA and anthracyclines
We report an increased incidence of high relapse
risk features in 157 APL Brazilian patients. Out of
134 patients treated with ATRA and anthracy-
clines, only 91 (67.9%) achieved remission because
43 (32%) died during induction. The death rate
during consolidation was 10.5%. Bleeding compli-
cations were the most frequent cause of failure
(21.6%).
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There is sufficient evidence in literature to support the
belief that all-trans retinoic acid (ATRA) and concomitant
anthracycline-based chemotherapy should be the treatment
of choice for newly diagnosed acute promyelocytic
leukemia (APL).1,2 In Brazil, APL accounts for more than
20% of acute myelogenous leukemias (AMLs),3 a higher
incidence than that reported in developed countries.
Nevertheless, despite the fact that anthracyclines and
ATRA are widely available, the results with standard treat-
ment are not known. 
We retrospectively analyzed  medical chart data of 157
APL patients treated from January 2003 to March 2006 at
12 Brazilian institutions. The diagnosis was based on detec-
tion of the t(15;17) chromosomal translocation by cytoge-
netic analysis or of PML/RARα rearrangement by RT-PCR
analysis. Laboratory diagnosis of disseminated intravascular
coagulation (DIC) was based on changes in activated partial
thromboplastin time, prothrombin time, fibrinogen degra-
dation products (FDPs), and/or D-dimers. Central nervous
system, pulmonary, or gastrointestinal hemorrhages were
considered a severe bleeding. Patients were classified
according to the risk of relapse on the basis of WBC and
platelet counts (PLT) at diagnosis: low risk, WBC ≤ 10×109/L
and PLT > 40×109/L; intermediate risk, WBC ≤ 10×109/L and
PLT ≤ 40×109/L; and high risk, WBC > 10×109/L.4
Survival analysis was carried out for 134 patients who
received anthracyclines (daunorubicin or idarubicin) plus
ATRA in induction, ATRA and anthracyclines (daunoru-
bicin, idarubicin, mitoxantrone or pharmarubicin) with  or
without citarabine in consolidation, and long term low
dose chemotherapy in maintenance as proposed by Fenaux
et al.5 Blood bank support was available in all the centers,
however, not all of them adopted prophylactic transfusions
based on fibrinogen concentrations. Early mortality was
defined as death within 14 days of diagnosis. Survival rates
were estimated by the Kaplan-Meier method, and com-
pared using the log-rank test. Differences among the risk
groups regarding frequencies of bleeding and DIC at diag-
nosis, and mortality rates were compared using the χ2 test.
APL patients represented 28.2% of AML cases in the ana-
lyzed population. This is consistent with the previously
reported higher frequency in patients with Latino ances-
try.6,7 The median WBC counts (Table 1) was higher than
those reported in literature.4,5 Consequently, the frequency
of high-risk patients was significantly higher than that
reported by PETHEMA and GIMEMA4 (36.9 vs 22.6%,
p=0.009). Although the time taken to reach specialized care
was not accessed, studies on other hematological malig-
nances suggest that this factor may be associated with the
frequency of high tumor burden.  The incidence of severe
bleeding did not differ from that previously reported8 but
was associated with high mortality. DIC, severe bleeding
and early mortality were more frequent in the high-risk
group (p=0.015, p=0.001 and p<0.001 respectively) (Table
1). PML-RARα isoform distribution did not differ from that
described in nonlatino populations.9 This is in contrast to
the reported excess of the BCR1 subtype in Mexican
Mestizos.10
Among 134 patients available for survival analysis,
13.4% died within 5 days of diagnosis and 26.4% died
within the first 14 days. This was mainly due to bleeding
(66.6%). Induction and consolidation mortality were
32.0% and 10.5% respectively (Table 1). Three patients
(2.2%) relapsed after consolidation and died. All patients
alive after induction where in hematologic remission. The
overall survival curves of all patients and of those who sur-
Table 1. Clinical  and laboratory features  and causes of mortality.
Value p
Age - mean (range), years 36 (5-79)
Sex - n (%)
Male 72 (45.8%)
Female 85 (54.2%)
WBC counts – median (range)×109/L 4.9 (0.3-403)
Platelet counts – median (range)×109/L 24 (5-193)
Risk assessment – n (%)
Low risk 29 (18.5%)
Medium risk 70 (44.6%)
High risk 58 (36.9%)
Severe bleeding at diagnosis - n (%) 27 (17.2%)
Low risk * 1 <0.001
Medium risk* 7
High risk * 19
Laboratory evidence of DIC 71 (45.2%) 0.012
at diagnosis - n (%)
Low risk* 12
Medium risk* 24
High risk * 35
BCR subtype (n/total)†
1 19/35
2 2/35
3 14/35
Early mortality§ - n (%) 33 (26.4%)
Low risk * 2 <0.001
Medium risk* 6
High risk* 25
Induction mortality§ - n (%) 43 (32.1%)
Causes of death
Bleeding 26 (60.5%)
ATRA syndrome 4 (9.3%)
Bleeding and ATRA syndrome 4 (9.3%)
Bleeding and infection 2 (4.7%)
Bleeding, infection and ATRA syndrome 3 (7.0%)
Infection and ATRA syndrome 1 (2.3%)
Unknown/other 3 (7.0%)
Consolidation mortality§ - n (%) 14 (10.5%)
Causes of death
Bleeding 3 (21.4%)
Infection 4 (28.6%)
Bleeding and infection 2 (14.3%)
Relapse 1 (7.1%)
Unknown/other 2 (14.3%)
Maintenance mortality§ - n (%) 3 (2.2%)
Mean Survival – days (CI, 95%)
Overall 706.7 (583.7-819.7)
Induction mortality excluded 1045.5 (593.7-819.7)
Low risk* 896.6 (747.0-1046.1 <0.001
Medium risk* 848.8 (678.6-1019.0)
High risk* 319.6 (190.6-448.5)
*Relapse risk groups; . §From 134 patients available for survival analysis;
†Data from 35 patients was available for BCR subgroup analysis.
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vived beyond induction are shown in Figures 1A and B
respectively. The comparative analysis of these two curves
reinforces the hypothesis that support during induction is
the major issue to be addressed in developing countries. No
significant differences were found between centers (data
not shown). As high risk patients had a higher early mortal-
ity (Table 1), risk classification may identify patients who
need a specific assessment, not only in consolidation, but
also more intensive supportive care during induction.
Two important issues require particular attention. In the
present study, no patient was excluded on the basis of age
or performance status. This contrasts with published clini-
cal trials and suggests that the prognosis of APL is not as
favorable as is sometimes stated. Neither is the availability
of drugs per se sufficient to reduce the gap in outcome
between APL patients in developed and those in develop-
ing countries. Quicker diagnosis and  better supportive care
are required. With this aim, the International Consortium
on Acute Promyelocytic Leukemia created a unified simpli-
fied treatment protocol and a support network offering on-
line bi-weekly conferences with specialists, guidelines and
monitoring of supportive care, centralized monitoring of
treatment response by molecular biology methods, and an
internet data base of patients from Brazil, Mexico and
Jordan. We hope that this program will help change the dis-
appointing results reported here.
Rafael Henriques Jácomo,1 Raul Antonio Morais Melo,2
Fernanda Ribeiro Souto,2 Éderson Roberto de Mattos,3
Claudia Teresa de Oliveira,2 Evandro M. Fagundes,4
Henrique Neves da Silva Bittencourt,4 Rosane Isabel Bittencourt,5
Teresa Cristina Bortolheiro,6 Eduardo J.A. Paton,7 Rodrigo Bendlin,8
Sebastião Ismael,9 Maria de Lourdes Chauffaille,10 Dirceu Silva,11
Katia Borgia B. Pagnano,12 Raul Ribeiro,13 Eduardo M. Rego1
1Department of Internal Medicine, Medical School of Ribeirao Preto,
Brazil; 2Molecular Biology Laboratory, HEMOPE, Brazil;
3Bone Marrow Transplantation Unit, Hospital Amaral Carvalho,
Brazil, 4Hematology Service, University of Minas Gerais, Brazil;
5Hematology and Bone Marrow Transplantation Unit, HCPA, Brazil;
6Hematology Service, Santa Casa de São Paulo, Brazil; 7Fundação
Pio XII de Barretos, Brazil; 8Hematology Service; HCPR, Brazil;
9Clínica de Hematologia de Ribeirão Preto, Brazil; 10Department of
Hematology and Hemotherapy, UNIFESP, Brazil; 11Oncominas,
Brazil; 12Hemocentro, State University of Campinas, Brazil;
13International Outreach Program,
St. Jude Children’s Research Hospital, Memphis, TN, USA
Acknowledgments: the authors would like to thank Margaret
Carbaugh for her critical review of the manuscript.
Key words: acute promyelocytic leukemia, ATRA, developing
countries, Brazil.
Correspondence: Eduardo Magalhães Rego, Laboratório de
Hematologia, Hospital das Clínicas da Faculdade de Medicina de
Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900,
Ribeirão Preto, São Paulo, 14048900, Brazil. Phone: international
+55.16.36022888. Fax: international +55.16.36336695.
E-mail: emrego@hcrp.fmrp.usp.br
References
1. Avvisati G, Lo CF, Diverio D, Falda M, Ferrara F, Lazzarino
M, et al. AIDA (all-trans retinoic acid + idarubicin) in
newly diagnosed acute promyelocytic leukemia: a Gruppo
Italiano Malattie Ematologiche Maligne dell'Adulto
(GIMEMA) pilot study. Blood 1996;88:1390-8.
2. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas
C, et al. Risk-adapted treatment of acute promyelocytic
leukemia with all-trans-retinoic acid and anthracycline
monochemotherapy: a multicenter study by the PETHE-
MA group. Blood 2004;103:1237-43. 
3. Onsten T, Girardi FM, Coelho GM, Lima Frey MC,
Paskulin G. Cytogenetic and morphological findings in 166
patients with de novo acute myeloid leukemia in southern
Brazil. Cancer Genet Cytogenet 2006;170:167-70.
4. Sanz MA, Lo CF, Martin G, Avvisati G, Rayon C, Barbui T,
et al. Definition of relapse risk and role of nonanthracy-
cline drugs for consolidation in patients with acute
promyelocytic leukemia: a joint study of the PETHEMA
and GIMEMA cooperative groups. Blood 2000;96:1247-53.
5. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H,
Archimbaud E, et al. A randomized comparison of all tran-
sretinoic acid (ATRA) followed by chemotherapy and
ATRA plus chemotherapy and the role of maintenance
therapy in newly diagnosed acute promyelocytic
leukemia. The European APL Group. Blood 1999;94:1192-
200.
6. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins
KJ, Levine AM. High frequency of acute promyelocytic
leukemia among Latinos with acute myeloid leukemia.
Blood 1996;87:308-13.
7. Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga
I, Perez JJ, et al. Geographic differences in the incidence of
cytogenetic abnormalities of acute myelogenous leukemia
(AML) in Spain. Leuk Res 2006;30:943-8.
8. Visani G, Gugliotta L, Tosi P, Catani L, Vianelli N,
Martinelli G, et al. All-trans retinoic acid significantly
reduces the incidence of early hemorrhagic death during
induction therapy of acute promyelocytic leukemia. Eur J
Haematol 2000;64:139-44.
9. Douer D, Santillana S, Ramezani L, Samanez C, Slovak
ML, Lee MS, et al. Acute promyelocytic leukaemia in
patients originating in Latin America is associated with an
increased frequency of the bcr1 subtype of the PML/RARα
fusion gene. Br J Haematol 2003;122:563-70.
10. Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nunez V,
Gomez-Rangel JD, Ruiz-Delgado GJ. More on geographic
hematology: the breakpoint cluster regions of the
PML/RARα fusion gene in Mexican Mestizo patients with
promyelocytic leukemia are different from those in
Caucasians. Leuk Lymphoma 2004;45:1365-8.
Figure 1. Overall survival of APL patients treated with ATRA in
combination with anthracyclines in Brazil. A. Analysis of all
patients. B. Analysis excluding patients who died during induction. 
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